Tag: strategy

PHOENIX, June 30, 2025 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, applauds the Arizona Department of Transportation (ADOT) for adopting its $11.6 billion 2026–2030 Five-Year Transportation Facilities Construction Program, including more than $249 million for several planned improvement projects on the State Route 347 (SR 347) corridor.

DALIAN, China, June 30, 2025 (GLOBE NEWSWIRE) -- CBAK Energy Technology, Inc. (NASDAQ: CBAT) ("CBAK Energy" or the "Company"), a leading manufacturer of lithium-ion and sodium-ion batteries and comprehensive electric energy solutions in China, today announced that its wholly-owned subsidiary, China BAK Asia Holdings Limited ("China BAK"), has entered into a significant strategic partnership (the “Partnership”) with Anker Innovations Technology Co., Ltd. (Shenzhen Stock Exchange: 300866, “Anker Innovations”), a global leader in intelligent hardware and one of CBAK Energy’s largest customers. As part of this Partnership, CBAK Energy will establish a new battery cell manufacturing facility in Malaysia (the “Malaysian Project”), with construction beginning immediately. The facility is expected to commence mass production of the Company’s flagship LFP cylindrical battery models, 32140 and 40135, by the end of 2025.

CEO Emil Malak Discusses VoIP-Pal’s Legal Strategy and Market Vision in New CEOCFO Interview — Read the Full Q&A here

SINGAPORE, June 30, 2025 (GLOBE NEWSWIRE) -- Uni-Fuels Holdings Limited (NASDAQ: UFG), (“Uni-Fuels” or the “Company”), a global provider of marine fuel solutions headquartered in Singapore, today announced the opening of a new office in Shanghai. As part of the Company’s global expansion strategy, Uni-Fuels has also established an office in Dubai, located near Fujairah, in April.

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.